Neurogenic Inflammation After Traumatic Brain Injury: How Neuropeptides Like Substance P Amplify Brain Damage

TRP channels (TRPV1 and TRPA1) are activated by mechanical forces during brain injury, causing the release of substance P. This neuropeptide then drives multiple inflammatory processes: activating microglia and astrocytes, degranulating mast cells, promoting immune cell migration into the brain, and critically, increasing blood-brain barrier permeability through caveolae-mediated transcellular transport. This neurogenic inflammation creates a positive feedback loop with classical inflammation — bradykinin and prostaglandins from classical pathways further stimulate TRP channels, perpetuating neuropeptide release and escalating damage.

This is a narrative review that synthesizes existing evidence from molecular, cellular, and preclinical studies on neurogenic inflammation following traumatic brain injury. The authors integrate findings on TRP channel activation, substance P signaling, blood-brain barrier permeability changes, and glial cell activation to propose a unified model of neuroinflammatory amplification.

Clinical trials targeting inflammation after traumatic brain injury have repeatedly failed. This review proposes a compelling explanation: treatments have only addressed classical inflammation while ignoring the neurogenic component driven by substance P and other neuropeptides. If the neurogenic pathway is indeed a key initiating event, targeting it — or targeting both pathways simultaneously — could lead to the first effective anti-inflammatory therapies for brain injury.

Traumatic brain injury affects millions worldwide and remains without effective pharmacological treatment for secondary damage. The repeated failure of anti-inflammatory drugs in TBI clinical trials has been a major puzzle. This review reframes the problem by showing that neurogenic inflammation — driven by neuropeptides — may be the missing piece. The concept extends beyond TBI, as neurogenic inflammation is increasingly recognized in migraine, arthritis, and other conditions where substance P plays a role.

This is a review paper synthesizing existing evidence, not presenting new experimental data. The proposed model of neurogenic-classical inflammatory feedback has not been directly validated in a single comprehensive study. Clinical evidence for targeting both pathways simultaneously in TBI patients does not yet exist. The relative contributions of neurogenic versus classical inflammation may vary by injury type and severity.